17th North American Regional ISSX Meeting (October 16

P1

A Method For Monitoring Drug Exposure In Hematopoietic Stem Cell Transplant Recipients
Isabelle Laverdiere, CHUL Research Center; Patrick Caron, CHUL Research Center; Félix Couture, Hôtel-Dieu de Québec Hospital; Éric Lévesque, Pharmacogenomics Laboratory, CHUQ Research Center; Chantal Guillemette, Pharmacogenomics Laboratory, CHUQ Research Center and Faculty of Pharmacy, Laval University

P3

Absolute UGT Protein Quantification by LC-MS3
Richard King, PharmaCadence Analytical Services, LLC; Carmen Fernandez-Metzler, PharmaCadence Analytical Services, LLC; J. Larry Campbell, AB SCIEX

P4

Application of the Narrow Window Mass Extraction Technique for In Vitro ADME Screening in Drug Discovery
Barry Press, Ontario Institute for Cancer Research; Rima Al-Awar, Ontario Institute for Cancer Research; Ahmed Aman, Ontario Institute for Cancer Research

P5

Comparison of High Resolution Accurate Mass Spectrometry and Triple Quadrupole MRM in Quantitative Bioanalysis
Yuan-qing Xia, AB SCIEX; Ragu Ramanathan, Bristol-Myers Squibb; Suma Ramagiri, MDS Analytical Technologies; Jeffrey D. Miller, AB SCIEX; Mohammed Jemal, Bristol-Myers Squibb

P6

Development of Collagenase as an Effective Tool in Tissue Homogenization for Bioanalytical Drug Quantitation
Ann Ran-Ran Qin, Genentech Inc.; Stephanie Dale, Genentech Inc.; Brian Dean, Genentech Inc.; Sheerin Shahidi-Latham, Genentech Inc.

P8

Dried Matrix Spot Analysis of Loxapine Phase II Metabolites in Rat Urine
Keith Huie, Alexza Pharmaceuticals Inc; Lori H. Takahashi, Alexza Pharmaceuticals Inc; Andrea Reed, Alexza Pharmaceuticals Inc; James Cassella, Alexza Pharmaceuticals Inc

P9

Evaluation of Accelerator Mass Spectrometry (AMS) Analysis at Two AMS Laboratories with Samples from a Microtracer Study of [¹⁴C]Saxagliptin in Dogs: Preparation for a Clinical Absolute Bioavailability Study
Lisa J. Christopher, Bristol-Myers Squibb; Xiaohui (Sophia) Xu, Bristol-Myers Squibb; Vikram Roongta, Bristol-Myers Squibb; Kai Cao, Bristol-Myers Squibb; Brad D. Maxwell, Bristol-Myers Squibb; Roger Demers, Tandem Labs; Bruce Stouffer, Bristol-Myers Squibb; Ali Arjomand, Accium Biosciences; Qi Song, Accium Biosciences; Stephen Dueker, Vitalea Sciences; Peter Lohstroh, Vitalea Sciences; Ramaswamy A. Iyer, Bristol-Myers Squibb; W. Griffith Humphreys, Bristol-Myers Squibb; Mark E. Arnold, Bristol-Myers Squibb

P10

Simultaneous Quantification Method of Human CYPs3A4, 3A7, 2B6, 2C9 and 2C19 in Humanaized Mouse Liver Microsomes
Yasuko Tsukazaki, Mitsubishi Chemical Medience Corporation; Naoto Senda, Mitsubishi Chemical Medience Corporation; Shin-ichiro Nitta, Mitsubishi Chemical Medience Corporation; Yasutoshi Ito, K. K. AB SCIEX; Shigeru Yamada, K. K. AB SCIEX; Yasuhiro Kazuki, Tottori University; Kinya Kubo, Tottori University; Mitsuo Oshimura, Tottori University

P11

Strategy to Increase Detection of Low Concentration of Radioactive Metabolites in Biological Fluids by HPLC Fractionation with Solid Scintillant Counting Using TopCount
Jie Chen, Johnson & Johnson Pharmaceutical Research and Development; Wing Lam, Johnson & Johnson Pharmaceutical Research and Development; Fran Xu, Johnson & Johnson Pharmaceutical Research and Development; Jose Silva, Johnson & Johnson Pharmaceutical Research and Development; Heng Keang Lim, Johnson & Johnson Pharmaceutical Research and Development